| HLT |
Report |
Adjusted EPS |
BEAT |
pred ~$2.30 vs. cons $2.276 |
MEDIUM |
| HLT |
Report |
System-wide RevPAR growth |
MISS |
pred ~3.20% vs. cons 3.38% |
MEDIUM |
| HLT |
Report |
Adjusted EBITDA |
IN-LINE |
pred ~$1.045B vs. cons $1.039B |
MEDIUM |
| HLT |
Guide |
FY2026 Adjusted EPS |
LOWER |
guide ~$8.79-$8.91 vs. cons $8.985 |
MEDIUM |
| HLT |
Guide |
FY2026 System-wide RevPAR growth |
LOWER |
guide ~2.0%-3.0% vs. cons 2.79% |
MEDIUM |
| HLT |
Guide |
FY2026 Adjusted EBITDA |
UNCHANGED |
guide ~$4.020B-$4.060B vs. cons $4.054B |
MEDIUM |
| HLT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| HLT |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — RevPAR miss and below-consensus FY guide pressure forward estimates |
LOW |